MLL3 has been reported to be a haploinsufficient tumor suppressor in AML,11 and thus we hypothesized that most MLL3 mutations in breast cancer would be heterozygous (Figure 1A).19, 20. The gene discussed is KMT2C; the disease is breast carcinoma.